These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 18701180

  • 1. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation.
    Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA.
    Radiother Oncol; 2008 Dec; 89(3):278-86. PubMed ID: 18701180
    [Abstract] [Full Text] [Related]

  • 2. Roedl JB et al., Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT comparison to histopathologic and clinical response evaluation, Radiother Oncol 2008; 89: 278-86.
    Fleming CE, Bass G, Walsh TN.
    Radiother Oncol; 2009 Aug; 92(2):291. PubMed ID: 19264369
    [No Abstract] [Full Text] [Related]

  • 3. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy.
    Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA.
    J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1232-41. PubMed ID: 15942562
    [Abstract] [Full Text] [Related]

  • 4. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy.
    Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, Correa AM, Mawlawi O, Ajani JA, Komaki RR, Fukami N, Erasmus JJ.
    Cancer; 2007 Jan 01; 109(1):125-34. PubMed ID: 17146785
    [Abstract] [Full Text] [Related]

  • 5. Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET.
    Sloof GW.
    Best Pract Res Clin Gastroenterol; 2006 Jan 01; 20(5):941-57. PubMed ID: 16997171
    [Abstract] [Full Text] [Related]

  • 6. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.
    Jacene HA, Leboulleux S, Baba S, Chatzifotiadis D, Goudarzi B, Teytelbaum O, Horton KM, Kamel I, Macura KJ, Tsai HL, Kowalski J, Wahl RL.
    J Nucl Med; 2009 Nov 01; 50(11):1760-9. PubMed ID: 19837757
    [Abstract] [Full Text] [Related]

  • 7. Tumor volume assessment by 18F-FDG PET/CT in patients with oral cavity cancer with dental artifacts on CT or MR images.
    Baek CH, Chung MK, Son YI, Choi JY, Kim HJ, Yim YJ, Ko YH, Choi J, Cho JK, Jeong HS.
    J Nucl Med; 2008 Sep 01; 49(9):1422-8. PubMed ID: 18703597
    [Abstract] [Full Text] [Related]

  • 8. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
    Krause BJ, Herrmann K, Wieder H, zum Büschenfelde CM.
    J Nucl Med; 2009 May 01; 50 Suppl 1():89S-96S. PubMed ID: 19380406
    [Abstract] [Full Text] [Related]

  • 9. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.
    Roedl JB, Harisinghani MG, Colen RR, Fischman AJ, Blake MA, Mathisen DJ, Mueller PR.
    Ann Thorac Surg; 2008 Oct 01; 86(4):1131-8. PubMed ID: 18805147
    [Abstract] [Full Text] [Related]

  • 10. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
    Odawara S, Kitajima K, Katsuura T, Kurahashi Y, Shinohara H, Yamakado K.
    Eur J Radiol; 2018 Apr 01; 101():65-71. PubMed ID: 29571803
    [Abstract] [Full Text] [Related]

  • 11. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M, Alnaji RM, Jabi F, Platz TA, Attwood K, Nava H, Ben-David K, Mattson D, Salerno K, Malhotra U, Kanehira K, Gannon J, Hochwald SN.
    JAMA Surg; 2015 Jun 01; 150(6):555-62. PubMed ID: 25902198
    [Abstract] [Full Text] [Related]

  • 12. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
    De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M.
    J Clin Oncol; 2009 Jul 10; 27(20):3303-11. PubMed ID: 19451443
    [Abstract] [Full Text] [Related]

  • 13. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
    Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S, Incarbone M, Alloisio M, Santoro A.
    J Clin Oncol; 2006 Oct 01; 24(28):4587-93. PubMed ID: 17008700
    [Abstract] [Full Text] [Related]

  • 14. Volumetric parameters of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography/computed tomography can predict histopathologic treatment response after neoadjuvant chemoradiotherapy in pancreatic adenocarcinoma.
    Sakane M, Tatsumi M, Hori M, Onishi H, Tsuboyama T, Nakamoto A, Ota T, Eguchi H, Wakasa K, Hatazawa J, Tomiyama N.
    Eur J Radiol; 2017 Sep 01; 94():64-69. PubMed ID: 28712692
    [Abstract] [Full Text] [Related]

  • 15. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V, Lucey JA, Duffy GJ, Wilson L, McNamara L, Keogan M, Gillham C, Reynolds JV.
    J Nucl Med; 2010 Dec 01; 51(12):1863-9. PubMed ID: 21078796
    [Abstract] [Full Text] [Related]

  • 16. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M, Omloo JM, van Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch OR, Tilanus HW, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Cuesta MA, Ten Kate FJ, Pruim J, van Dekken H, Bergman JJ, Sloof GW, van Lanschot JJ.
    Ann Surg; 2011 Jan 01; 253(1):56-63. PubMed ID: 21233607
    [Abstract] [Full Text] [Related]

  • 17. Intratreatment Response Assessment With 18F-FDG PET: Correlation of Semiquantitative PET Features With Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy.
    Tandberg DJ, Cui Y, Rushing CN, Hong JC, Ackerson BG, Marin D, Zhang X, Czito BG, Willett CW, Palta M.
    Int J Radiat Oncol Biol Phys; 2018 Nov 15; 102(4):1002-1007. PubMed ID: 30055238
    [Abstract] [Full Text] [Related]

  • 18. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
    Lastoria S, Piccirillo MC, Caracò C, Nasti G, Aloj L, Arrichiello C, de Lutio di Castelguidone E, Tatangelo F, Ottaiano A, Iaffaioli RV, Izzo F, Romano G, Giordano P, Signoriello S, Gallo C, Perrone F.
    J Nucl Med; 2013 Dec 15; 54(12):2062-9. PubMed ID: 24136935
    [Abstract] [Full Text] [Related]

  • 19. Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus.
    Roedl JB, Halpern EF, Colen RR, Sahani DV, Fischman AJ, Blake MA.
    Mol Imaging Biol; 2009 Dec 15; 11(1):54-60. PubMed ID: 18769974
    [Abstract] [Full Text] [Related]

  • 20. Comparison of 18F-FDG positron emission tomography and computed tomography in patients with colorectal carcinoma and lymphoma: our initial clinical experience.
    Coha B, Radmilović K, Gardasanić J, Daković M, Stefanić M, Latić A, Mitrecić D.
    Acta Clin Croat; 2009 Mar 15; 48(1):35-9. PubMed ID: 19623870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.